Flamingo Therapeutics to Present Danvatirsen's Immuno-Modulatory Effects at AACR Annual Meeting 2025
Flamingo Therapeutics, a pioneering company in RNA-targeted therapies, has recently revealed that it will present at the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled from April 25 to 30 in Chicago, Illinois. The focus of their presentation will be on the immune-modulatory effects of danvatirsen, a promising agent in oncology.
About the Presentation
Flamingo has announced that an abstract has been accepted for presentation under the title: "ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies". This poster will be showcased in the Immunology session focusing on modulating the Tumor Microenvironment to enhance immunogenicity and counteract suppression. The presentation is scheduled for April 28, 2025, from 9:00 AM to 12:00 PM, in Poster Section 38. The abstract carries the publication number 2244, showcasing the research's significance.
Flamingo's Commitment to Innovation
Flamingo Therapeutics is dedicated to advancing RNA-targeted therapies specifically aimed at challenging areas in oncology, notably those involving undruggable transcription factors and long non-coding RNAs. Their collaboration with Ionis Pharmaceuticals highlights their commitment to innovation in this field. Additionally, the company has garnered support from reputable biotechnology investors, including Abrdn, Andera Partners, and Bpifrance, among others.
Clinical Trials and Future Outlook
In line with their research, Flamingo has embarked on a Phase II trial named 'PEMDA-HN', which is evaluating danvatirsen in conjunction with pembrolizumab for patients with head and neck squamous cell carcinoma (HNSCC). In parallel, a Phase I investigator-initiated trial is underway to analyze danvatirsen as a monotherapy and in combination with venetoclax in patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
This proactive approach demonstrates Flamingo's ambition to not only understand but also combat the complexities of cancer treatment. Their results at the AACR Annual Meeting could have lasting implications, possibly leading to new standards of care in oncology therapeutics.
To learn more about Flamingo Therapeutics and their promising research, visit their official website at flamingotx.com. For further details regarding the ongoing trials, you can check clinicaltrials.gov for PEMDA-HN and the danvatirsen study.
The scientific community eagerly awaits the insights from Flamingo's presentation, which could significantly influence the treatment landscape for cancer therapies. Engagement on professional platforms like LinkedIn will allow medical professionals and investors to stay connected with Flamingo's evolving contributions to oncology.
About the Presentation
Flamingo has announced that an abstract has been accepted for presentation under the title: "ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies". This poster will be showcased in the Immunology session focusing on modulating the Tumor Microenvironment to enhance immunogenicity and counteract suppression. The presentation is scheduled for April 28, 2025, from 9:00 AM to 12:00 PM, in Poster Section 38. The abstract carries the publication number 2244, showcasing the research's significance.
Flamingo's Commitment to Innovation
Flamingo Therapeutics is dedicated to advancing RNA-targeted therapies specifically aimed at challenging areas in oncology, notably those involving undruggable transcription factors and long non-coding RNAs. Their collaboration with Ionis Pharmaceuticals highlights their commitment to innovation in this field. Additionally, the company has garnered support from reputable biotechnology investors, including Abrdn, Andera Partners, and Bpifrance, among others.
Clinical Trials and Future Outlook
In line with their research, Flamingo has embarked on a Phase II trial named 'PEMDA-HN', which is evaluating danvatirsen in conjunction with pembrolizumab for patients with head and neck squamous cell carcinoma (HNSCC). In parallel, a Phase I investigator-initiated trial is underway to analyze danvatirsen as a monotherapy and in combination with venetoclax in patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
This proactive approach demonstrates Flamingo's ambition to not only understand but also combat the complexities of cancer treatment. Their results at the AACR Annual Meeting could have lasting implications, possibly leading to new standards of care in oncology therapeutics.
To learn more about Flamingo Therapeutics and their promising research, visit their official website at flamingotx.com. For further details regarding the ongoing trials, you can check clinicaltrials.gov for PEMDA-HN and the danvatirsen study.
The scientific community eagerly awaits the insights from Flamingo's presentation, which could significantly influence the treatment landscape for cancer therapies. Engagement on professional platforms like LinkedIn will allow medical professionals and investors to stay connected with Flamingo's evolving contributions to oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.